Register
Community
Overview
Experts
Editors
Fellows
Code of conduct
AI Guidelines for Physicians
Company
About Us
FAQs
Privacy Policy
Terms of Use
Careers
Programs
News
News Releases
Press Coverage
Publications
Blog
Contact Us
Sign in
Please select the option that best describes you:
Topics:
Gynecologic Oncology
•
Medical Oncology
When do you recommend adjuvant trastuzumab for completely resected uterine cancer and for how long do you give it?
Related Questions
What are your top takeaways from SGO 2025?
What is your experience with in vitro chemosensitivity testing?
Would you offer systemic chemotherapy to a patient with at least 2023 FIGO stage IC high grade serous (p53-mut) endometrial cancer with extensive LVI for whom nodal assessment was not done?
What are your top takeaways in Gyn Cancers from ASCO 2025?
For a patient with locally current endometrial cancer whose disease had complete radiographic response to carboplatin, Taxol, and pembrolizumab, would you consider adding radiation therapy?
Given the negative results of GOG-0238 but the positive results of the RUBY trial, how do you manage isolated vaginal cuff recurrence of endometrial cancer?
Are there patient populations in whom you would consider using both induction chemotherapy and maintenance pembrolizumab for a patient with locally advanced cervical cancer?
How would you manage a patient with FIGO stage IIIB endometrial carcinoma who developed significant back pain with Carboplatin/Paclitaxel cycle 1, which worsened during cycle 2?
How do you manage the chemotherapy portion of chemoradiation in a patient with stage IIIB (hydronephrosis) cervical cancer patient on hemodialysis?
Would you use a GI regimen (FOLFOX) or a GYN regimen (Carboplatin/Paclitaxel +/- immuno) for a 71yo women with ascites, a large pelvic mass arising from the uterus (on CT), and peritoneal implants that are CDX2 positive, PAX 8 / WT-1 negative, p53 wild type, intestinal type?
